Moreover, alteration of the p53 pathway has been reported to be observed in NSCLC with activating EGFR mutations suggesting that p53 inactivation is required to allow expansion of a cell with EGFR pathway activation (Mounawar et al, 2007). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.